GT 1908
Alternative Names: GT-1908; PALI-1908Latest Information Update: 22 Aug 2024
Price :
$50 *
At a glance
- Originator Giiant Pharma
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Crohn's disease
Most Recent Events
- 13 Aug 2024 Palisade Bio has notice to grant patent from European Patent Office
- 06 Sep 2023 Giiant Pharma and Palisade Bio enters into an exclusive worldwide license agreement for Giiant’s proprietary targeted prodrug platform for therapies targeting inflammatory bowel disease
- 31 Aug 2021 Early research in Crohn's disease in USA (PO)